News & Updates

Show Multimedia Only

RW data support enfortumab vedotin-pembrolizumab combo as 1L Tx for bladder cancer

12 Mar 2026 by

Real-world (RW) data presented at ASCO GU 2026 support the use of enfortumab vedotin plus pembrolizumab (EV+P) as frontline treatment for advanced urothelial carcinoma (UC).

RW data support enfortumab vedotin-pembrolizumab combo as 1L Tx for bladder cancer

12 Mar 2026

Belzutifan-lenvatinib bests cabozantinib for RCC

11 Mar 2026 by

A combination regimen comprising belzutifan and lenvatinib outdoes cabozantinib alone for the treatment of advanced clear cell renal cell carcinoma (ccRCC) in the phase III LITESPARK-011 study.

Belzutifan-lenvatinib bests cabozantinib for RCC

11 Mar 2026

Sacituzumab tirumotecan feasible in advanced urothelial carcinoma

03 Mar 2026 by

Treatment with sacituzumab tirumotecan (sac-TMT) shows a promising antitumour activity and an acceptable safety profile in patients with heavily pretreated advanced or metastatic urothelial carcinoma (UC), according to a phase II study.

Sacituzumab tirumotecan feasible in advanced urothelial carcinoma

03 Mar 2026

Original New Drug Application Approvals by US FDA (1-15 February 2026)

02 Mar 2026

New drug applications approved by US FDA as of 1-15 February 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 February 2026)

02 Mar 2026

Women working in service industry at greater risk for LUTS

24 Feb 2026

A recent study has found that employment in managerial and professional positions across early and mid-adulthood may result in a reduced risk for lower urinary tract symptoms (LUTS) at midlife, while that in service positions tends to increase such risk.

Women working in service industry at greater risk for LUTS

24 Feb 2026

Positive ctDNA predicts metastasis in MIBC after TMT

24 Feb 2026 by

Plasma circulating tumour DNA (ctDNA) can act as a biomarker for the early detection of metastatic progression in patients with muscle-invasive bladder cancer (MIBC) treated with bladder-sparing trimodality therapy (TMT), suggests a study.

Positive ctDNA predicts metastasis in MIBC after TMT

24 Feb 2026

Investigational oral antibiotic noninferior to dual therapy for uncomplicated gonorrhoea

03 Feb 2026 by

In the treatment of uncomplicated urogenital gonorrhoea, a single dose of the novel oral antibiotic zoliflodacin shows similar efficacy and safety profile as the ceftriaxone plus azithromycin combination, as shown in a multinational phase III study.

Investigational oral antibiotic noninferior to dual therapy for uncomplicated gonorrhoea

03 Feb 2026

Patient participation lacking in prostate cancer consultations

30 Jan 2026

A recent study has noted high variability in patient participation in consultations for clinically localized prostate cancer, with no consistent predictors. Moreover, time spent in expressing preferences, values, or the decision-making process is minimal.

Patient participation lacking in prostate cancer consultations

30 Jan 2026

New model predicts febrile UTI in children with VUR after CAP discontinuation

29 Jan 2026

Select children with persistent vesicoureteral reflux (VUR), especially those without voiding dysfunction, may choose to suspend continuous antibiotic prophylaxis (CAP), suggests a study, noting that a predictive monogram can aid in individualized decision-making.

New model predicts febrile UTI in children with VUR after CAP discontinuation

29 Jan 2026

SGLT2 inhibitors may keep ADT working longer in prostate cancer

23 Jan 2026 by

In prostate cancer patients receiving androgen deprivation therapy (ADT), concurrent use of SGLT2 inhibitors appears to delay hormone therapy failure.

SGLT2 inhibitors may keep ADT working longer in prostate cancer

23 Jan 2026

News & Updates

Showing Urology articles

Showing

Specialty:

RW data support enfortumab vedotin-pembrolizumab combo as 1L Tx for bladder cancer

RW data support enfortumab vedotin-pembrolizumab combo as 1L Tx for bladder cancer

Belzutifan-lenvatinib bests cabozantinib for RCC

Belzutifan-lenvatinib bests cabozantinib for RCC

Sacituzumab tirumotecan feasible in advanced urothelial carcinoma

Sacituzumab tirumotecan feasible in advanced urothelial carcinoma

Original New Drug Application Approvals by US FDA (1-15 February 2026)

Original New Drug Application Approvals by US FDA (1-15 February 2026)

Women working in service industry at greater risk for LUTS

Women working in service industry at greater risk for LUTS

Positive ctDNA predicts metastasis in MIBC after TMT

Positive ctDNA predicts metastasis in MIBC after TMT

Investigational oral antibiotic noninferior to dual therapy for uncomplicated gonorrhoea

Investigational oral antibiotic noninferior to dual therapy for uncomplicated gonorrhoea

Patient participation lacking in prostate cancer consultations

Patient participation lacking in prostate cancer consultations

New model predicts febrile UTI in children with VUR after CAP discontinuation

New model predicts febrile UTI in children with VUR after CAP discontinuation

SGLT2 inhibitors may keep ADT working longer in prostate cancer

SGLT2 inhibitors may keep ADT working longer in prostate cancer